Open Australia-wide: LOW DOSE NALTREXONE FOR THE TREATMENT OF POST COVID-19 CONDITION

Quick extraction of text from image
NATIONAL CENTRE FOR NEUROIMMUNOLOGY AND EMERGING DISEASES

LOW DOSE NALTREXONE FOR THE TREATMENT OF POST COVID-19 CONDITION

Project Overview

Long COVID describes the presence of various COVID-19 symptoms three months after infection lasting for at least two months. To date, there is no evidence-based treatment for Long COVID. Naltrexone (NTX) is an opioid receptor blocker commonly used to treat opioid withdrawal. However, since the mid-1980s, low dose NTX (LDN) has been used off-label due to improvements in chronic pain, stamina, cognition, fatigue, and inflammation. LDN has since been used for many autoimmune disorders, chronic pain syndromes, malignancies, and mental health disorders to target symptoms overlapping with Long COVID.This project aims to determine if treatment with LDN improves fatigue, cognitive and health-related quality-of-life (HRQOL) in adults with Post COVID Condition (PCC). If this is the case, LDN may offer a safe and cost- effective treatment for PCC and potentially similar disorders.

We are recruiting the following participants:
Diagnosed with Long COVID according to WHO working case definition and present with the following symptoms: cognitive disturbances otherwise known as brain fog, sleep disturbances and/or body pain.

The inclusion criteria are as follows:
•
Aged between 18 and 65 years of age
• BMI between 18.5 and 29.9
•
Not pregnant or breastfeeding
Not taking routine medications including opioids or substitution therapy, DMARDS, steroids, minocycline, and metformin.
• No previous diagnoses of ME/CFS
The Study Involves:
•
Completion of a series of online questionnaires
• Trial period of 13 weeks
• Randomised placebo-controlled trial with dose escalation
Appointments between research staff and participants will be via phone or virtual video conference platforms, such as Teams or Zoom. LDN will be distributed monthly via registered post, so there is no need to travel to a research site.
There is no incentive from completing this trial; however your involvement will help determine if treatment with LDN will improve patient severity and HRQOL in people with Long COVID. This flyer was reviewed approved by Griffith University Ethics Committee.
If you are interested in participating, please contact us:
(07) 5678 9283
ncned@griffith.edu.au
facebook.com/NCNED
Griffith
UNIVERSITY
SCAN ME

 

Facebook post today:
-

NCNED is inviting people with ME/CFS, people with long COVID and healthy volunteers to participate in ongoing and upcoming research projects at our Centre, including our clinical trial investigating Low-Dose Naltrexone (LDN) as a potential treatment for long COVID.

We are also seeking your help for studies investigating the pathomechanisms of and potential treatments for ME/CFS and long COVID by donating blood, attending a neuroimaging scan or completing online questionnaires.

Best wishes,
Sonya and the NCNED Team

 

So none of the most severe people.

Is there a protocal we can look at? I wonder how blinded it will be and how they are going to deal with dosing.